Cato Research is a full-service contract research and development organization with international resources dedicated to helping pharmaceutical and biotechnology companies efficiently and expeditiously navigate the regulatory approval process in order to bring new drugs, biologics, and medical devices to the people who need them.
» Cato Research Overview | Contact Us
July 27, 2010 - Generic Lovenox – Moving One Step Closer to Biosimilars – Lovenox is not, I repeat, not a biologic therapeutic. It is derived from a biological source (pig intestines, yum), but it is not protein-based. However, the FDA's approval of a generic form [...]
July 26, 2010 - Statistical Implications of Protocol Amendments – Clinical trial protocol amendments occur for good reasons. An unanticipated safety issue may arise, new information about the disease or treatment may suggest alterations, or recruitment and enrollment [...]
July 21, 2010 - HHS Proposes Changes to HIPAA – On July 8th, the Department of Health and Human Services (HHS) announced that it was proposing changes to Health Insurance Portability and Accountability Act's (HIPAA's) privacy rules. These changes [...]
July 2010 - Cato Research Presents at BIOCOM CRO Workshop: Pre-IND Meetings and IND Submissions: Lessons Learned
August 2, 2010 - 6:00 PM - Cato Research Presents at NC East SoCRA Chapter Meeting: Informed Consent Content & Process Requirements
October 8-12, 2010 - Cato Research Presents at 35th ESMO Congress in Milan
June 21, 2010 - Cato Research Names Dr. Erik Berglund, MD, PhD, RAC (US, EU) as Associate Managing Director of Cato Research San Francisco Office ![]()
May 20, 2010 - Merge Healthcare and Cato Research Ltd. Establish New Five-Year Technology Transfer Agreement